Antibody-drug conjugate

From Self-sufficiency
Jump to: navigation, search

Antibody-drug conjugates (ADCs) are a new type of targeted therapy eg for cancer.[1] [2] [3] [4] They consist of an antibody (or antibody fragment such as a single-chain variable fragment (scFv)) linked to a payload drug (often cytotoxic). Hence they are a type of immunoconjugate.

The antibody causes the ADC to bind to the target cancer cells. Often the ADC is then internalised by the cell and the drug is released to do its damage.[5]

Approved:

Examples in clinical trials :[1][6]

Phase III : none as of early 2008

Phase II:

Phase I:

Preclinical:

References

Cite error: Invalid <references> tag; parameter "group" is allowed only.

Use <references />, or <references group="..." />
  1. 1.0 1.1 http://pharmtech.findpharma.com/pharmtech/Ingredients+Insider/Antibody-Drug-Conjugates-A-Marriage-of-Biologics-a/ArticleStandard/Article/detail/522139
  2. http://pubs.acs.org/doi/abs/10.1021/bc9002019
  3. http://cancerres.aacrjournals.org/content/66/6/3214.abstract
  4. http://www.ncbi.nlm.nih.gov/pubmed/17553616
  5. http://cancerres.aacrjournals.org/content/52/1/127.full.pdf+html Immunoconjugates Containing Novel Maytansinoids: Promising Anticancer Drugs. Chari et al. 1992
  6. http://pharmtech.findpharma.com/pharmtech/data/articlestandard//pharmtech/232008/522139/i3.jpg ADCs in early 2008
  7. http://www.cancer.gov/drugdictionary/?CdrID=564399
  8. http://www.news-medical.net/news/20100827/FDA-denies-accelerated-approval-of-Genentechs-trastuzumab-DM1-%28T-DM1%29-BLA-for-metastatic-breast-cancer.aspx
  9. http://www.asco.org/ASCOv2/Meetings/Abstracts?&vmview=abst_detail_view&confID=65&abstractID=33509
  10. http://www.news-medical.net/news/20091206/ImmunoGen-reports-encouraging-clinical-data-of-IMGN901.aspx
  11. http://www.ncbi.nlm.nih.gov/pubmed/12525512 Cantuzumab mertansine, a maytansinoid immunoconjugate directed to the CanAg antigen: a phase I, pharmacokinetic, and biologic correlative study. 2003 Abstract
  12. http://jco.ascopubs.org/content/21/2/211.full Cantuzumab Mertansine, a Maytansinoid Immunoconjugate Directed to the CanAg Antigen: A Phase I, Pharmacokinetic, and Biologic Correlative Study. Tolcher et al. 2003. Full text
  13. http://www.nature.com/leu/journal/vaop/ncurrent/abs/leu2010141a.html